Ligand Pharmaceuticals | LGND - Gross Profit On Sales


Ligand Pharmaceuticals reported $48.45M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Agenus USD 34.2M 4.61M Dec/2025
Amgen USD 6.89B 415M Dec/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Baxter International USD 891M 314M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Enviri Corporation USD 83.01M 37.46M Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 256.46M 38.78M Mar/2026
Intrexon USD -297K 167K Jun/2024
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Ligand Pharmaceuticals USD 48.45M 8.22M Mar/2026
MacroGenics USD 31.11M 30.14M Dec/2025
Merck USD 10.85B 2.57B Dec/2025
Pacira USD 126.64M 15.61M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Veracyte USD 101.16M 814K Mar/2026